BioPharmaSynergy 2022

BIOPharmaSynergy

#BioPharmaSynergy 2022 is taking place on 22-23rd of February in Amsterdam (and online)

Examine the biosimilar market development status: hear from global and local players, discuss successful commercialisation strategies, partnerships and consider the current competitive challenges, approvals, and uptakes.

BioPharmaSynergy logo

PRODUCT PORTFOLIO:  #biosimilars, #biobetters, #bioinnovative products

 

GEOGRAPHIC COVERAGE: Worldwide

 

BioPharmaSynergy is built around B2B partnering meetings that connect global Business Development professionals focused on #biosimilars, #biobetters, #bioinnovative_medicines. In addition to B2B partnering, the event offers a content-driven agenda focusing on successful commercial strategies, pricing consideration, facilitating partnering across mature and emerging markets and between producers and buyers.

 

First Speaker Confirmations

Thiago no background

Thiago Rennó dos Mares Guia, Scientific & Business Executive Director, Bionovis

Bert Thomas, Senior Vice President, Business Development, Bio-Thera Solutions

Bert Thomas, SVP Business Development, Bio-Thera Solutions

Gopal Rao, Deputy General Manager, Global BD & Licensing, Lupin

Gopal Rao, Deputy General Manager, Global BD & Licensing, Lupin

Huiguo Hu, Chief Commercial Office & Senior Vice President & Board Director, Mabwell Bioscience

Huiguo Hu, Chief Commercial Office & Senior Vice President & Board Director, Mabwell Bioscience

Sandoz

Sangeeta Gupta Nair, Head BD & Licensing Biosimilars (International Region), Sandoz

Toksoz CEO Arven

Zafer Toksoz, President and Founder, Arven Pharmaceuticals

Atabay

Doğan Taşkent, Director, R&D and Innovation, Atabay Pharmaceuticals

Mauritz Venter, Co-founder & CEO, AzarGen (StartUp Showcase)

Mauritz Venter, Co-founder & CEO, AzarGen (StartUp Showcase)

Ricardo Martín Castro Acosta NEOLPHARMA

Ricardo Martín Castro Acosta, Head R&D Biotechnology, Neolpharma

Dr H. 2016 Photo

Jeffrey Hausfeld, Chairman of the Board & Chief Medical Officer, BioFactura

TOPICS and highlights

Bidding on cost competitiveness and biosimilar capabilities to drive commercial sustainability and the global scale

Overview of the global biosimilar landscape by region: North America, Europe, LATAM, MENA, APAC

Competitive space evolution and companies’ strategies in the innovative biologics and biosimilars

 

Choosing the right partner and capabilities for the strategic alliances – what are the key considerations?

Analyzing the difference of global pricing, competition, and marginality in European and non-European markets

Status of the biosimilar market development: approvals, regulatory developments, and future outlook

Watch the highlights of the Buyers & Sellers discussion that took place at #BioPharmaSynergy 2021